Fbw7 and
Introduction
Deregulation of the cell cycle can lead to uncontrolled proliferation, defects in chromosome segregation and ultimately cancer development [1] [2] [3] . Therefore, proteins required for proper cell cycle progression must be tightly regulated and perform their functions only when needed. Ubiquitin ligases are key components of this control as they ubiquitinate key regulators of the cell cycle machinery, signaling for their destruction [4] . Two major classes of E3 ligases, SKP1-CUL1-F-box protein (SCF)-and Anaphase Promoting Complex/Cyclosome (APC/C)-type ubiquitin ligases, are known to target multiple substrates crucial for cell cycle progression [5, 6] . SCF complexes require F-box proteins for target identification, while APC/C utilizes activators, such as Cdh1 and Cdc20, for substrate recognition [4] . These two families of proteins orchestrate the temporal expression of cell cycle controllers and ensure restricted cell proliferation and faithful DNA segregation.
One well-studied F-box protein is F-box and WD repeat domain-containing 7 (Fbw7). The first member of this gene family was originally identified in budding yeast, and was named Cdc4 [7] . Human Fbw7 is located on chromosome 4 and encodes three transcripts (isoforms α, β and γ) [8] . These three isoforms vary at the N-terminal region, but contain conserved interaction domains in the C terminus (F-box and WD40 repeats). The F-box motif of each F-box protein is a region of approximately 40 amino acids that recruits other subunits of the SCF complex by interacting with S-phase kinase-associated protein 1 (Skp1) [9] , thus allowing the formation of a functional E3 ligase complex [5, 10] . Also, the C-terminal region of Fbw7 contains a stretch of eight WD40 repeats that bind phosphorylated substrates [11, 12] . Characterized substrates of Fbw7 include cyclin E, c-Myc, c-Jun, and NOTCH-1, all of which are well-known products of oncogenes involved in a variety of human tumors [6, 7, 13] . Not surprisingly, Fbw7 is a tumor suppressor whose mutations occur in multiple neoplasms including breast cancer, colon cancer and leukemia [14] [15] [16] [17] [18] . Approximately 6% of all primary human tumors harbor mutations in the Fbw7 gene with the highest mutation rates found in cholangiocarcinoma and T-cell acute lymphoblastic leukemias (T-ALL) [7] . The roles of SCF Fbw7 substrates in tumorigenesis have been well documented. However, how Fbw7 suppresses tumor formation is currently not well understood. Although negative regulation of c-Myc and NOTCH-1 by Fbw7 has been implicated in tumorigenesis, their contributions to the tumor suppressor function of Fbw7 still require substantial characterization [16, [18] [19] [20] . On the other hand, cyclin E has garnered much attention as a possible key mediator for the ability of Fbw7 to inhibit tumorigenesis. To that end, Lengauer and colleagues [21] demonstrated that loss of Fbw7 function led to genomic instability that could be suppressed by the additional depletion of cyclin E. Furthermore, a cyclin E mutant (T380A) that cannot be degraded by Fbw7 induced genomic instability more effectively than wild-type (WT) cyclin E [22] . Moreover, mice with the murine equivalent of the T380A mutation exhibited chromosomal instability and increased cancer development [23] . Although emerging evidence suggests that controlling Cdk2/cyclin E kinase activity likely accounts for the tumor suppressor function of Fbw7, considerable amount of work is still needed to elucidate the exact role of cyclin E in tumorigenesis. The best-characterized function of cyclins is to bind and activate cyclindependent kinases (CDKs), leading to phosphorylation of downstream substrates [24] . Thus, it is critical to pinpoint the major downstream targets of cyclin E, which may mediate the tumor suppressor function of Fbw7. Interestingly, Cdk2/cyclin E was reported to inactivate APC
Cdh1
, through direct phosphorylation of its activator, Cdh1 [25] .
APC/C is a well-characterized E3 ligase important for genomic stability and a known tumor suppressor [26] . Cdh1 is an activator and a substrate-recognition subunit of the APC/C E3 ligase. Unlike F-box proteins that bind phosphorylated substrates, activators of APC/C recognize Destruction Box (D-Box) or KEN Box motifs [27, 28] . Substrates of APC Cdh1 include proteins important for G1 stability (cyclin A, cyclin B1 and Skp2), DNA synthesis (Cdc6 and Geminin) and mitosis (Aurora A and Plk) [29] [30] [31] [32] . Therefore, APC Cdh1 is a critical regulator of cell cycle progression. As aforementioned, aberrant cell cycle regulation can often lead to missegregation of chromosomes, resulting in aneuploidy. Not surprisingly, many reports have implicated Cdh1 function in maintaining proper genomic stability [26, [33] [34] [35] . In addition, multiple APC Cdh1 targets have also been documented for their oncogenic capabilities. Elevated levels of Skp2 can promote the development of prostate carcinomas [36] and facilitate the transformation of Rat1 cells [37] . Both Plk1 and Aurora A are also amplified in various tumors and their expression correlates with poor clinical prognosis [38, 39] . Furthermore, transgenic mice overexpressing cyclin A develop acute myeloid leukemia [40] . Although Cdh1 displays many characteristics of a bona fide tumor suppressor, only recently has this been established. GarciaHiguera et al. [26] demonstrated that heterozygous Cdh1 mice (Cdh1 +/− ) develop epithelial tumors, suggesting a haploinsufficient role of Cdh1 in tumor suppression. Moreover, reduced Cdh1 expression was observed in hematological neoplasias and solid tumors [33] . As loss of Cdh1 function can have multiple effects that predispose cells to transformation, it is critical to understand its regulatory pathways.
Our present study has identified a novel signaling link between the Fbw7 and Cdh1 tumor suppressor pathways. Fbw7 governs the E3 ligase activity of APC Cdh1 by modulating the expression of cyclin E. Thus, in Fbw7-deficient cells, elevated cyclin E expression leads to the inactivation of APC Cdh1 via direct phosphorylation of Cdh1. This subsequently results in elevation of multiple known APC Cdh1 substrates, many of which are well-characterized oncoproteins. These findings highlight a critical role of Fbw7 in suppressing tumorigenesis. Loss of Fbw7, which is frequently observed in various human cancers, can lead to aberrant inactivation of both the Fbw7 and Cdh1 signaling pathways, thus providing a mechanistic insight into the tumor suppressive function of Fbw7.
Results

Depletion of Fbw7 leads to aberrant elevation of APC
Cdh1 substrates
Loss of Fbw7 activity is frequently observed in many types of human cancers, with the highest mutation rates found in T-ALL (approximately 30%) [7] . Interestingly, we noticed that in Fbw7-deficient T-ALL cell lines, besides the SCF Fbw7 substrate cyclin E, the expression of
npg APC Cdh1 substrates cyclin B and cyclin A was also elevated ( Figure 1A) . However, the underlying mechanism accounting for this upregulation is currently unclear. Similarly, elevated expression of other APC Cdh1 substrates such as Plk1 and Cdc20 was also observed in Fbw7-deficient breast cancer cell lines (Supplementary information, Figure S1A ). These results indicate a possible crosstalk between the Fbw7 and Cdh1 tumor suppressor pathways. We further demonstrated that compared with WT DLD1 colon cancer cells, loss of Fbw7 led to a significant induction of various APC Cdh1 substrates including cyclin A, cyclin B, Plk1, Cdc20 and Skp2 ( Figure 1B and Supplementary information, Figure S1B ). Moreover, we observed a significant decreased expression of various Skp2 substrates including p130, p57 and p27, consistent with the model that loss of Fbw7 leads to reduced Cdh1 activity, which subsequently causes elevated Skp2 activity ( Figure 1B) .
Furthermore, FACS analysis indicated that depletion of Fbw7 did not cause a significant change in cell cycle progression ( Figure 1C and 1D) , suggesting that the change in APC Cdh1 substrates was not a secondary effect derived from gross misregulation of the cell cycle. Furthermore, we did not observe a significant change in Cdh1 expression after loss of Fbw7, suggesting that Fbw7 does not regulate APC Cdh1 substrates by modulating the abundance of Cdh1 itself ( Figure 1B and 1E) . Consistently, shRNA-mediated depletion of Fbw7α and Fbw7γ, and to a lesser extent, Fbw7β, led to a similar upregulation of APC Cdh1 substrates as that observed in Fbw7
−/− cells ( Figure 1E and Supplementary information, Figure  S1C ). Furthermore, reintroduction of WT-Fbw7 led to a dramatic decrease in the expression of various Cdh1 substrates in the Fbw7 −/− DLD1 cells ( Figure 1F ), suggesting a causal relationship between the loss of Fbw7 function and the aberrant upregulation of APC Cdh1 substrates.
Cyclin E plays a central role in mediating the ability of Fbw7 to regulate APC Cdh1 substrate abundance Although multiple SCF Fbw7 substrates have been identified, it is still unclear how they contribute to the tumor suppressor function of Fbw7. A recent study [21] has highlighted a possible role of cyclin E in mediating the ability of Fbw7 to suppress tumorigenesis, as depletion of cyclin E rescued the genomic instability observed in Fbw7 −/− cells. Additionally, cyclin E has been implicated in regulating Cdh1 activity [25] . These clues prompted us to further investigate whether cyclin E is the major route through which Fbw7 modulates APC Cdh1 substrate abundance. Indeed, we found that depletion of cyclin E via multiple independent shRNA lentiviral vectors led to marked decreases in the expression of the APC Figure 2C ). Interestingly, depletion of cyclin E did not significantly change Rb phosphorylation or Cdt1 expression pattern ( Figure 2B ), indicating that the observed changes in the Cdh1 signaling pathway in cyclin E-depleted cells were not due to gross changes in the cell cycle or DNA replication process. Conversely, we found that overexpression of WT or a non-degradable form of cyclin E (T380A) in WT DLD1 cells could also lead to the aberrant APC Cdh1 substrate expression similar to that observed in Fbw7 −/− cells ( Figure 2D and Supplementary information, Figure  S2A ). However, an elevation in Rb phosporylation, but not in the expression of Cdt1, was observed after cyclin E overexpression ( Figure 2D ). Nonetheless, as depletion of cyclin E reversed the aberrant APC Cdh1 substrate expression in Fbw7 −/− cells ( Figure 2B ), it suggests that cyclin E plays a central role in mediating the ability of Fbw7 to regulate APC Cdh1 substrate abundance. Consistently, both treatment with the Cdk2 inhibitor Roscovitine and depletion of Cdk2 via multiple independent shRNA vectors led to a sharp decrease in APC Cdh1 substrates in Fbw7 −/− cells ( Figure 2E , 2F and Supplementary information, Figure S2B ), suggesting that the kinase activity of Cdk2/cyclin E might be required for the inactivation of APC Cdh1 in Fbw7 −/− cells. It has been recently reported that Cdk2/cyclin E could phosphorylate Cdh1, leading to its dissociation from the APC core subunit [25] . Consistent with this report, we observed an obvious reduction in Cdh1 binding to the APC core subunit in Fbw7 −/− cells ( Figure 2G ).
Fbw7 regulates the stability of various APC Cdh1 substrates
As Cdh1 is the activator of the APC/C E3 ligase, and the interaction between Cdh1 and the APC core subunit was reduced in Fbw7 −/− cells ( Figure 2G ), we suggest that Fbw7 regulates Cdh1 and APC Cdh1 substrates at a post-translational level. Consistently, we did not observe significant changes in the mRNA levels of Cdh1 ( Figure  3A) or the APC Cdh1 substrates Cdc20 ( Figure 3B ) and Skp2 ( Figure 3C ) in Fbw7 −/− DLD1 cells compared with the WT DLD1 cells. On the other hand, using either Cycloheximide [41, 42] or Anisomycin [43] to block protein synthesis as a means to measure protein stability, we Figure S3B and S3I-S3M), further supporting the critical role of cyclin E in mediating the ability of Fbw7 to regulate APC Cdh1 substrate stability. Consistent with the role of Fbw7 in regulating APC Cdh1 E3 ligase activity, we found that the ubiquitination of the APC Cdh1 substrate Plk1 is significantly decreased in Fbw7 −/− cells compared with that in WT cells ( Figure 3N and Supplementary information, Figure S3C ). More importantly, we found that preincubation with recombinant Cdk2 and cyclin E proteins dramatically decreased the ability of WT-Cdh1, but not that of the non-phosphorylatable 4A-Cdh1 mutant (Figure 4A and 4B), to activate the APC E3 ligase in the in vitro ubiquitination assays using cyclin B as the substrate ( Figure 3O ). This indicates that Cdk2/cyclin E might directly phosphorylate Cdh1, leading to its inactivation [25] ( Figure 6 ) .
Cdk2/cyclin E directly phosphorylates Cdh1 at multiple sites, leading to the inactivation of the APC
Cdh1 E3 ubiquitin ligase APC Cdh1 is a master regulator of the G1/S cell cycle transition and thus its E3 ligase activity is tightly regulated. It was previously reported that phosphorylation of Cdh1 by Cdk2/cyclin A at multiple sites (S40, T121, S151 and S163) located at the N terminus of Cdh1 could lead to the dissociation of Cdh1 from the APC/C core subunit, thus terminating the E3 ligase activity of APC Cdh1 before S phase entry [44] . Later work by Keck et al. [25] expanded this finding by demonstrating that Cdk2/cyclin E could also phosphorylate Cdh1 to inactivate Cdh1. However, they did not completely specify the phosphorylation sites involved in the inactivation of Cdh1. To better understand the molecular mechanism by which cyclin E inactivates Cdh1, we performed in vitro kinase assays and defined that similar to Cdk2/cyclin A (Supplementary information, Figure S4A ), Cdk2/cyclin E mainly phosphorylates Cdh1 at the four pinpointed sites ( Figure 4A and 4B). Next, we performed in vivo degradation assays to explore how Cdk2/cyclin E-mediated phosphorylation of Cdh1 affects its ability to promote the destruction of the APC Cdh1 substrates Plk1 and cyclin B. As illustrated in Figure 4C -4E, overexpression of WT-Cdh1 enhanced the destruction of both Plk1 and cyclin B, a process that can be inhibited by ectopic expression of Cdk2 and cyclin E. On the other hand, the ability of 4A-Cdh1 to enhance the destruction of either Plk1 or cyclin B was not affected by expression of either cyclin E or a non-degradable version of cyclin E (T380A) together with Cdk2. These results clearly demonstrated that elevated expression of cyclin E, which is observed in Fbw7-deficient cells, could lead to inactivation of the APC Cdh1 E3 ligase and subsequent elevation of APC Cdh1 substrates. As the mode of negative regulation of Cdh1 activity relies on Cdk2/cyclin E-dependent phosphorylation of Cdh1, the 4A-Cdh1 mutant that cannot be phosphorylated by Cdk2/cyclin E should maintain its ability to activate APC/C E3 ligase even in the Fbw7 −/− genetic background. Consistent with this reasoning, we found that doxycycline-induced expression of 4A-Cdh1, but not WT-Cdh1, led to a decrease in the expression of various APC Cdh1 substrates in Fbw7 . As illustrated in Figure 4G , compared with WT or the 4A mutant form of Cdh1, the phospho-mimetic mutant form of Cdh1 (4D) displayed a significant reduction in association to the APC core subunit. More importantly, we further demonstrated that ectopic expression of cyclin E led to an increase in the phosphorylation of endogenous Cdh1 ( Figure 4H ), whereas depletion of cyclin E resulted in a sharp decrease in endogenous Cdh1 phosphorylation ( Figure 4I ). Therefore, consistent with previous reports [25, 44, 45] , these results support a model that the Fbw7/cyclin E signaling pathway potentially regulates the E3 ligase activity of APC Cdh1 by affecting the interaction of Cdh1 with the APC core subunit primarily through regulating Cdh1 phosphorylation status ( Figure 6 ).
Negative regulation of APC Cdh1 E3 ligase activity by cyclin E contributes to the tumor suppressor function of Fbw7
Next, we characterized the physiological significance of the signaling link between the Fbw7 and Cdh1 tumor suppressor pathways. Consistent with the tumor suppressor role of Fbw7, we found that loss of Fbw7 led to increased entry into the S phase, as illustrated by elevated BrdU labeling ( Figure 5A and 5B). Furthermore, depletion of cyclin E ( Figure 5A and 5B), or Cdk2 ( Figure 5C and 5D [25] , our work implicated Cdk2/cyclin E as a critical negative regulator of Cdh1 activity. We further defined that doxycycline-induced ectopic expression of 4A-Cdh1, but not WT-Cdh1, also led to a significant decrease in BrdU incorporation in Fbw7 −/− cells ( Figure 5E and 5F), suggesting that cyclin E functions in part through the Cdh1 signaling pathway to influence S phase entry. Additionally, we found that depletion of cyclin E in Fbw7 −/− cells also led to a marked decrease in cell migration when compared with cells infected with shGFP as negative control (Supplementary information, Figure S5A ). Notably, doxycycline-induced expression of 4A-Cdh1 is more efficient than WT-Cdh1 in suppressing anchorageindependent colony formation in Fbw7 −/− cells ( Figure  5G and 5H) . However, this difference is not obvious in WT DLD1 colon cancer cells (Supplementary information, Figure S5B and S5C). These results indicate that elevated Cdk2/cyclin E-dependent phosphorylation of WT-Cdh1, but not 4A-Cdh1, in Fbw7 −/− cells inactivates the tumor suppressor function of Cdh1. More importantly, using a xenograft mouse model, we showed that depletion of cyclin E in Fbw7 −/− DLD1 cells significantly retarded their ability to form tumors in vivo ( Figure 5I , 5J, Supplementary information, Figure S5D and S5E). Furthermore, consistent with the finding that depletion of cyclin E reduced Cdh1 phosphorylation ( Figure 4I ), we found that compared with tumors derived from mice injected with shGFP-treated cells, shcyclin E-treated Fbw7 −/− DLD1 tumors exhibited a significant reduction in endogenous Cdh1 phosphorylation ( Figure 5K ). Together, these results suggest that Fbw7 regulates the Cdh1 tumor suppressor pathway through a cyclin Edependent mechanism ( Figure 6 ). Hence, loss of Fbw7 activity likely creates a scenario equal to loss of both the Fbw7 and Cdh1 tumor suppressor pathways, facilitating tumorigenesis.
Discussion
In this study, we present evidence for a possible model that loss of Fbw7 function promotes tumorigenesis by inactivating the APC Cdh1 E3 ligase via cyclin E upregulation ( Figure 6 ). In multiple colon cancer cell lines with a loss of the Fbw7 gene, elevated expression was observed not only for SCF Fbw7 substrates, including cyclin E, but also for APC Cdh1 substrates, including cyclin B, cyclin A, Plk1 and Skp2 ( Figure 1B and Supplementary information, Figure S1B ). Most importantly, this aberrant APC Cdh1 substrate expression phenotype was rescued upon depletion of cyclin E in Fbw7 −/− cells (Figure 2A  and 2B ), while overexpression of cyclin E in WT cells could faithfully phenocopy the aberrant APC Cdh1 substrate expression found in Fbw7 −/− cells ( Figure 2D and Supplementary information, Figure S2A ). These results suggest that cyclin E is a possible signaling link between these two tumor suppressor pathways that were previously thought to be mutually exclusive. Furthermore, these results also advocate for the usage of specific Cdk2/ cyclin E inhibitors for treating Fbw7-deficient tumors. However, we also recognize that inactivation of Cdh1 by cyclin E might not be the only mechanism accounting for the tumor suppressor function of Fbw7 [5, 7] , and more thorough studies are still required to fully elucidate other signaling pathways that may also play roles in mediating the tumor suppression function of Fbw7.
In addition to connecting the Fbw7 and Cdh1 tumor suppressor pathways, our work also further characterizes the molecular mechanism by which elevated levels of cyclin E can lead to APC Cdh1 inactivation. While it was recently reported that phosphorylation of Cdh1 by Cdk2/cyclin E led to the dissociation of Cdh1 from the −/− DLD1 cells were infected with an shcyclin E lentiviral vector (with an shGFP vector as a negative control) followed by selection in 1 µg/ml puromycin for 72 h to eliminate the non-infected cells before the synchronization. (C) Immunoblot analysis of WCL derived from Fbw7 −/− DLD1 cells stably infected with the indicated shRNA lentiviral vectors followed by transfection with a vector encoding an shRNA-resistant cyclin E [26] 
or an empty vector as a negative control. (D) Immunoblot analysis of Fbw7
−/− or WT DLD1 cells synchronized by growth in nocodazole, and then released for the indicated periods of time. Where indicated, WT DLD1 cells were infected with a retrovirus vector encoding WT cyclin E or a non-degradable version of cyclin E (T380A) (with the empty vector as a negative control) followed by selection in 1 µg/ml puromycin for 72 h to eliminate the non-infected cells before the synchronization. npg APC core subunit [25] , the exact phosphorylation sites involved in the regulation were not completely identified. Here we show that four sites present at the N terminus of Cdh1 (S40, T121, S151 and S163), which are the sites important for Cdk2/cyclin A-dependent regulation of APC Cdh1 activity, are also critical for Cdk2/ cyclin E-dependent negative regulation of Cdh1 ( Figure  4B-4D) . Furthermore, our findings extend the cyclin ECdh1 regulatory axis by including Fbw7 as an upstream component of this pathway (Figure 6 ). We also seek to demonstrate the physiological significance of the Fbw7-cyclin E-Cdh1 regulatory axis as frequent loss of Fbw7 is a major cause of cyclin E overexpression in human cancers. To this end, our results clearly show that depletion of cyclin E in Fbw7 −/− cells retarded cell entry into S phase ( Figure 5A and 5B). This is likely attributed to cyclin E-dependent inactivation of Cdh1 as depletion of cyclin E reversed the aberrant upregulation of APC Cdh1 substrates ( Figure 2B ). Furthermore, doxycyclineinduced expression of a non-phosphorylatable Cdh1 also resulted in delayed S phase entry ( Figure 5E and 5F), mimicking the cyclin E-depletion phenotype. These findings therefore fill in the gap of knowledge regarding how Fbw7 governs the activity of Cdh1 to exert its anti-tumor functions.
With Cdh1 playing such a vital role in mediating the degradation of major cell cycle regulators, it is not surprising that Cdh1 was recently characterized to be a bona fide tumor suppressor [26] . Therefore, understanding how the tumor suppressor function of Cdh1 is regulated becomes increasingly more important. However, we recognize that as APC Cdh1 has been reported to target numerous substrates, many of which are putative oncoproteins, for ubiquitination and degradation; further thorough studies are required to pinpoint the exact downstream target(s) of APC Cdh1 that mediates its tumor suppressor function. Notably, in comparison to the frequent loss of Fbw7 in multiple types of human neoplasias, mutations in Cdh1 gene are not commonly observed [46] . Therefore, the signaling axis described in this study not only sheds lights on how Fbw7 functions as a tumor suppressor, but also on how Cdh1 is inactivated by means other than loss-of-function mutations or changes in Cdh1 protein abundance during cancer development. In this sense, loss of Fbw7 provides an umbrella effect that indirectly leads to the inactivation of APC Cdh1 . Thus our work provides a possible explanation for the lower frequency of Cdh1 mutations in human cancers. Similar overarching effects have also been observed for the p53/ p21 and TSC2/mTOR signaling pathways [47] [48] [49] . Due to the high frequency of p53 and TSC2 mutations, p21 or mTOR mutations are much less frequent in human cancers. Furthermore, our findings also begin to highlight how Fbw7 can act as such a potent tumor suppressor, as loss of Fbw7 function would lead to the inhibition of two tumor suppressor pathways.
Materials and Methods
Expression constructs and shRNAs
HA-Fbw7 was obtained from Dr Keiichi I Nakayama (Kyushu University, Japan). HA-cyclinE-WT and HA-cyclin E-T380A were obtained from Dr Wade Harper (Harvard University). To construct pBabe-Puro-HA-cyclin E-WT and -T380A, human cyclin E-WT and -T380A cDNA was subcloned into the pBabe-Puro vector. Myc-Cdh1-WT and Myc-Cdh1-4A were obtained from Dr Jiri Lukas (Institute of Cancer Biology and Centre for Genotoxic Stress Research, Denmark). To generate the pGEX-Cdh1 truncation constructs (Cdh1-WT (N174) and Cdh1-4A (N174)) used in the in vitro kinase assays, truncated Cdh1 cDNA was amplified by PCR from Myc-Cdh1-WT or Myc-Cdh1-4A and the PCR product was Bacterially purified GST-NTcyclin B proteins were incubated with the APC complex purified from G1-phase HeLa extracts together with purified E1, E2 and ubiquitin proteins at 30 °C for 60 min before being resolved by SDS-PAGE and probed with the anti-HA antibody. In vitro translated WT-or 4A-Cdh1 was added to activate the APC E3 ligase complex. Where indicated, WT-or 4A-Cdh1 was preincubated with the recombinant Cdk2/cyclin E prior to performing the in vitro ubiquitination assay. 
Cell culture and cell synchronization
Cell culture and cell synchronization experiments were performed as previously described [41, 50] . Lentiviral shRNA packaging and infection were also performed as previously described [51] . The Cdk inhibitor roscovitine (Cell Signaling) was used as indicated. The T-ALL cell lines were generous gifts from Dr Ronald DePinho (MD Anderson Cancer Center) while the breast cancer cell lines were generous gifts from Dr Alex Toker (Harvard University). The WT-Fbw7 and Fbw7 −/− colon cancer cell lines (DLD1 and HCT116) were kindly provided by Dr Bert Vogelstein (Johns Hopkins University).
Immunoblots and immunoprecipitation
Cells were lysed in EBC buffer (50mM Tris pH 7.5, 120mM NaCl, 0.5% NP-40) supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem). Protein concentrations were then measured using a Bio-Rad protein assay reagent on a Beckman Coulter DU-800 spectrophotometer. Finally, the lysates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. For Cdc27 immunoprecipitation, 1 mg of lysate was incubated with anti-Cdc27 conjugated to agarose beads (Santa Cruz Biotechnology) overnight at 4 °C. Immunocomplexes were then washed 5 times with NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40) and resolved by SDS-PAGE and immunoblotted with the indicated antibodies.
In vitro kinase assay
For use in in vitro kinase assays, active Cdk2/cyclin E and Cdk2/cyclin A were purchased from Millipore and NEB, respectively. The protocol followed was previously described by Inuzuka et al. [42] . Briefly, 2.5 µg of the indicated GST fusion proteins were incubated with active Cdk2/cyclin E or Cdk2/cyclin A in the presence of 0.5 µCi [γ-
32 P] ATP and 200 µM cold ATP in Cdk2/cyclin kinase buffer. The reaction was allowed to proceed for 30 min before being stopped by the addition of SDS-containing loading buffer. The samples were then resolved by SDS-PAGE.
In vivo ubiquitination analysis
In vivo ubiquitination assays were performed as described previously [42, 52] . Briefly, cells were transfected with plasmids encoding HA-Plk1 along with Myc-ubiquitin. Thirty-six hours af- −/− DLD1 cells were infected with a Tet-inducible lentiviral vector encoding Myc-WT-Cdh1 or Myc-4A-Cdh1 (or with empty vector as a negative control), followed by selection in 1 µg/ml puromycin for 72 h to eliminate the noninfected cells before addition of Dox for 16 h to induce the expression of Cdh1. Afterwards, the indicated cells were plated into soft agar-containing medium for anchorage-independent colony growth assays. Every 3-4 days, new fresh medium or Doxcontaining medium was added as indicated. ter transfection, 10 µM MG132 was added to inhibit proteasomal degradation. Cells were then harvested in EBC buffer containing protease inhibitors and the collected whole-cell lysates (1 mg) were incubated with anti-HA beads (Sigma) or anti-Myc beads (Santa Cruz Biotechnology) for 4 h. After incubation, the precipitates were washed 6 times with NETN buffer, and the washed pellet was boiled in SDS-containing sample buffer and resolved by SDS-PAGE.
In vitro ubiquitination analysis
APC
Cdh1 in vitro ubiquitination assays were performed as described previously [53] . Briefly, 8 µg of anti-Cdc27 (AF3.1) antibodies coupled to 80 µl of protein A-agarose (Sigma) were incubated with 0.8 ml extracts of HeLa cells released 3 h from nocodazole arrest and mixed for 2 h at 4 °C. The beads were washed three times with 1 ml swelling buffer (SB, 25 mM HEPES, pH7.5, 1.5 mM MgCl 2 , 5 mM KCl) supplemented with 0.05% Tween 20 and twice with SB. Finally, the beads were resuspended in 40 µl of SB and aliquoted into 8 tubes (5 µl for each tube). Purified APC complexes were further activated by incubation with IVT-Cdh1 for 45 min as indicated. To generate the phosphorylated Cdh1, IVTCdh1 was treated with active cyclin E/Cdk2 and 100 µM ATP for 30 min at 30 °C prior to the incubation with APC complexes. 0.15 µM E1, 1 µM UBCH10, 1 mg/ml ubiquitin, Energy mix (7.5 mM creatine phosphate, 1 mM ATP, 1 mM MgCl 2 , 0.1 mM EGTA), and 1 U creatine phosphokinase were mixed in UBAB buffer (25 mM Tris/HCl, pH7.5, 50 mM NaCl, 10 mM MgCl 2 ) in a final volume of 8 µl. Reactions were started by the addition of bacterially expressed and purified GST-cyclin B-NT (1-119) as substrate, incubated for 60 min at 30 °C, resolved by SDS-PAGE and immunoblotted with the GST antibody.
Cell migration assay
Cell migration assays were performed as previously described [54] . Briefly, 1 × 10 5 cells in serum-free media containing 0.1% BSA were added to the upper chamber of a Transwell Filter (8 µm pore size; Corning) in triplicates. NIH 3T3-cell-conditioned media was added to the lower chamber. After a 16-h incubation at 37 °C, non-migrated cells at the top of the filter were removed using a cotton swab. Cells that had migrated to the bottom of the filter were fixed and stained using the Hema-3 stain set (purchased from Protocol). Cells were then counted using a 20× objective, and four fields were chosen per well with three wells per each condition.
Bromodeoxyuridine (BrdU) labeling
BrdU labeling was performed as described previously [55] . The experiments were performed 3 times to generate error bars.
Soft agar colony formation assay
Soft agar growth assays were performed as described previously [56] . Briefly, 24 h before plating, cells were treated with 100 ng/ml of doxycycline to induce expression of the various Cdh1 constructs. At the time of plating in soft agar, cultures were trypsinized and counted, and 1 × 10 4 total cells were mixed with 1.5 ml of 0.4% Noble agar-DMEM (top layer) and then poured on top of 5 ml of solidified 0.8% Noble agar-DMEM (bottom layer) in 6-cm diameter dishes. Cells were fed weekly by overlaying 1 ml of growth media supplemented with doxycycline as indicated. After 3 weeks, colonies were stained with 1 mg/ml iodomi tetrazolium chloride, counted and pictures were taken. The experiment was performed three times to generate error bars.
Real-time RT-PCR analysis
RNA was extracted with a Qiagen RNeasy mini kit, and the reverse transcription reaction was performed with ABI Taqman Reverse Transcriptional Reagents (N808-0234). After mixing the resulting template with ABI Taqman Fast Universal PCR Master Mix (4352042) and Cdh1 (FZR1) (Hs00393592_m1), Cdc20 
FACS analysis
FACS analysis was performed as previously described [50] .
Xenograft mouse model
In vivo tumorigenesis assays were performed as previously described [42] . Briefly, 2.5 × 10 6 cells were injected into the hind flank of male nude mice. Tumor size was measured every 3-4 days after initial tumor growth using a caliper. The tumor volume was then determined using the formula: L × W 2 × 0.52, where L is the longest diameter and W is the shortest diameter of the measured growth.
